Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595736 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3200327 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT02595736 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 52 participants.
The verdict
NCT02595736, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the safety and tolerability of single doses of LY3200327 when given to healthy male and female participants either by injection under the skin or by drip into a vein. The study will help determine how the drug behaves inside the body and how long it takes to disappear from the body. The study will also look for anti-drug antibodies and how these may affect how LY3200327 acts in your body. The study is expected to last approximately 12 weeks (with screening evaluations up to 4 weeks prior).
Interventions
- DRUG Placebo (SC)
- DRUG Placebo (IV)
- DRUG LY3200327 (SC)
- DRUG LY3200327 (IV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02595736
The ClinicalTrials.gov registry entry for NCT02595736 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo (SC) is the first listed.
NCT02595736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02595736 about?
NCT02595736 is a clinical study titled "A Study of LY3200327 in Healthy Participants". The purpose of this study is to look at the safety and tolerability of single doses of LY3200327 when given to healthy male and female participants either by injection under the skin or by drip into a vein. The study will help determine how the drug behaves inside the body and how long it takes to d...
What is the current status of trial NCT02595736?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2015-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02595736?
The interventions under investigation include: Placebo (SC) (DRUG), Placebo (IV) (DRUG), LY3200327 (SC) (DRUG), LY3200327 (IV) (DRUG).
Who is sponsoring clinical trial NCT02595736?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.